Deep sustained response to daratumumab monotherapy associated with T-cell expansion in triple refractory myeloma.

ABSTRACT:

Background

Daratumumab, a human CD38 monoclonal antibody that has direct on-tumor and immunomodulatory mechanisms of action, demonstrated clinical benefit as monotherapy or in combination with established regimens in patients with multiple myeloma with one or more prior lines of therapy.

Case presentation

A male patient, who was 70 years of age at the time of diagnosis of multiple myeloma in 2011, relapsed after five lines of therapy, including autologous stem cell transplantation. The patient's disease, which was considered high risk with a deletion of chromosome 17p, advanced quickly and was triple refractory 2 years after diagnosis leaving few treatment options. He was treated with daratumumab monotherapy in the SIRIUS clinical trial resulting in a stringent complete resp

SUBMITTER: Usmani SZ 

PROVIDER: S-EPMC5804097 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature